RBC Capital analyst Gregory Renza downgraded Verrica Pharmaceuticals (VRCA) to Sector Perform from Outperform with a price target of $2, down from $11. The firm says the company’s “challenging” Q3 of negative net revenues is compounded by a quick CEO transition and strategic review to save Ycanth, manage costs, and restore the balance sheet. RBC sees “an uncertain path” for Verrica and cut its Ycanth forecasts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRCA:
- Verrica downgraded to Sector Perform from Outperform at RBC Capital
- Verrica Pharmaceuticals: Financial Struggles Amid Strategic Shifts
- Verrica Pharmaceuticals Undergoes Leadership and Financial Restructuring
- Verrica Pharmaceuticals reports Q3 EPS (43c), consensus (37c)
- Verrica to preset results on VP-315 at Fall Clinical Dermatology Conference